Denmark’s Xellia hiring at Ohio plant, hopes to begin manufacturing next year

Xellia looks to begin sterile injection production at Ohio plant in 2018.

Xellia Pharmaceuticals, the maker of anti-infective treatments, is hiring at the former Ben Venue Labs in Bedford, Ohio, as it prepares to begin drug manufacturing at the site next year.

The facility, at which the Copenhagen-based company received FDA approval in 2016 for packaging and distribution operations, still needs approval from the regulatory agency to begin sterile injectable drug production.

A spokesman for the company, Niels Lynge Agerbaek, told that the facility is on track to receive the approval in 2018. Currently, most of the products packaged and distributed from the Bedford site come from the company's European facilities.

"A huge amount of renovation has been going on,” Agerbaek told the news site. “We're operating with upgraded equipment and we're getting all the paperwork together to make sure we are in compliance to pass inspection.”

The company is looking to fill about 70 positions for mechanics and operators right now, but is expected to broaden the hiring in the coming months for engineering, quality assurance and supply-chain jobs. So far, Xellia has hired about 130 people to work in its laboratories and warehouse and distribution center.

Suggested Articles

GBA offers Brexit escape, Merck and Just - Evotech to share production space, GSK ointment line in Bangladesh may reopen and more news of note.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.